Prostacyclins, which play a major role in therapy of severe IPAH and HPAH, inhibit TGFβ1 signaling and enhance BMP/BMPR2 signaling [41, 42]. The gene discussed is BMPR2; the disease is idiopathic pulmonary arterial hypertension.